The pet supplement industry is clearly entering a maturity phase. The early years were driven by enthusiasm, humanization, and the rapid transfer of human supplement trends into pet formats. What’s changing now is the expectation that pet supplements must stand on their own scientific, formulation, and regulatory footing.

As we look ahead, marketing sophistication and spend will continue to drive short-term growth for many brands, particularly those built on lower-cost formulations. However, long-term credibility and staying power will increasingly favor products designed around credible science, biological relevance, and a genuine potential for efficacy, rather than formulations optimized primarily to subsidize marketing budgets.

One of the biggest gaps in pet supplements compared to human dietary supplements is the lack of species-specific clinical validation, standardized endpoints, and long-term outcome data. In humans, we benefit from established dosing models and biomarkers. In pets, we are still building that foundation.

A key challenge is pharmacokinetics and metabolic variability. A 2 kg dog and a 70 kg dog may both be “dogs,” but they do not absorb or metabolize ingredients the same way. Breed, size, age, and gut physiology all matter, yet standardized dosing models remain limited.

Human data can be helpful, but only as a starting signal. Certain compounds that are well tolerated or beneficial in humans can behave very differently in pets. Cats are a clear example. Their limited glucuronidation capacity means that ingredients commonly tolerated in dogs, or even considered benign in humans, can be unsafe or toxic to dogs & cats. This is why species-specific safety and efficacy work is not optional if the industry is serious about a “do no harm” standard.

Pet humanization has helped raise expectations around quality, transparency, and science, which is a positive shift. At the same time, it can create unrealistic expectations. Owners may expect supplements to produce rapid, visible changes similar to what they experience themselves. When that doesn’t happen, it can lead to “supplement hopping,” even if the product is delivering longer-term structural or cellular benefits. This “performance placebo” effect is a real challenge in both product design and consumer education.

From an ingredient supplier’s perspective, quality in pet supplements is non-negotiable.

One aspect of quality that is often underestimated is ingredient equivalence. Two products may list the same ingredient on a label while differing substantially in composition, standardization, and processing. Botanical extracts may lack defined active fractions, structural ingredients can vary widely in purity, and marine-derived materials may be processed in ways that remove lipid or co-factor components essential to their native function. When these differences are overlooked, inconsistent outcomes are frequently attributed to the ingredient category itself rather than to material quality or form. For formulators and practitioners, understanding ingredient identity beyond the label is foundational to achieving consistent results and maintaining long-term credibility.

Key parameters include identity and standardization where possible, form suitability for the species, purity and contaminant control, including heavy metals, oxidation, residues, and mycotoxins, and consistent batch-to-batch quality supported by comprehensive QA systems.

Pets often consume the same supplement every day for years. That reality elevates the importance of chronic exposure risk and long-term stability in a way that is sometimes underestimated when products are developed by simply adapting human formulations.

Palatability and real-world stability matter just as much as the ingredient itself. A supplement that looks great on paper but isn’t consumed consistently by the pet delivers no benefit at all.

It is unrealistic to expect pharmaceutical-style trials for every pet supplement. That said, claims still require a defensible evidence stack.

At a minimum, this should include a clear mechanistic rationale, appropriate bioavailability or pharmacokinetic work where relevant, targeted pet studies (pilot or observational), veterinary-guided real-world data, and strong manufacturing and stability documentation.

One of the biggest methodological challenges in pet research is the caregiver placebo effect. Owners want their pets to feel better, and that emotional investment can strongly influence reported outcomes. Owner feedback is valuable for quality-of-life indicators like energy or appetite, but it is inherently subjective. The most reliable insights come when owner observations are paired with double-blind designs, veterinary assessments, functional measures, or biomarkers.

In pet supplements, the “patient” (the pet) and the “payer” (the owner) have very different needs. A product only works if it is actually consumed.

Palatability remains one of the biggest formulation challenges, especially with high-potency botanicals and functional actives that are naturally bitter. Masking bitterness while maintaining a clean label and ingredient integrity is often the difference between a successful product and one that fails in market.

Format also plays a major role in compliance. Chews dominate because they feel like a treat. Powders offer flexibility and dosing control. Liquids can be useful for certain pets but can be messy to administer and introduce stability and oxidation challenges. There is no universally “best” format, only the format that works for a specific pet, owner routine, and use case.

Species differences are critical here. Cats are not small dogs. Beyond metabolic differences, cats are often neophobic and far more sensitive to changes in flavor and texture. Formulating for cats requires a fundamentally different approach rather than simply scaling down a canine product.

We continue to see strong demand for multi-active blends driven by owner convenience. Many pet owners prefer one all-in-one product rather than managing multiple SKUs.

That said, broad wellness products and condition-specific products serve different purposes. Multi-active blends can be effective for general maintenance, but they often cannot deliver the same level of targeted support for more serious needs as a well-designed, condition-specific SKU. The risk comes when convenience is mistaken for efficacy.

Sustainability has become a core purchasing driver, particularly in omega-3 sourcing. Alternative sources are gaining attention, but they are not interchangeable by default.

While some alternatives offer sustainability advantages, they do not always have the same depth of safety, stability, and long-term efficacy data in pets as traditional marine oils. Oxidation control, dosing efficiency, sensory performance, and cost all remain practical challenges. Transparency around both benefits and limitations is essential if trust is the goal.

Regulatory fragmentation remains one of the biggest challenges for global brands.

In the US, products often exist in a gray area between food and drug, requiring careful navigation of FDA and AAFCO expectations. In the EU, pre-market controls and claim restrictions are generally stricter. Across both regions, the highest risk continues to come from therapeutic or disease-implying claims.

As the category grows, scrutiny is increasing. This pressure, while challenging, is also an opportunity for higher-quality players to differentiate through discipline rather than exaggeration.

Veterinarians can play an important role here, not as gatekeepers, but as educators, when supported with credible science and technical documentation rather than marketing language.

Over the next 5–10 years, the long-term success of pet supplements will be determined by credibility. The single most impactful change would be full traceability.

It is realistic to expect that future pet supplements will carry a digital “passport” or QR code linking ingredient origin, manufacturing location, and batch-specific testing results. In a category where regulators cannot realistically police every bad actor, traceability may become the most effective trust mechanism available, shifting competition away from marketing spend and toward measurable quality, safety, and accountability.

The future of pet supplements lies in treating animals not as small humans, but as unique biological systems, and designing products that respect both the pet and the payer.